Device manufacturer Aptar Pharma announced that it will expand its production facility in Congers, NY, USA, including a significant increase in its capacity for manufacturing the Unidose (UDS) nasal delivery system. The expansion includes new cleanroom manufacturing, with additional molds and assembly lines for the nasal devices expected to come online by the end of 2024.
In 2022, Opiant Pharmaceuticals (now Indivior) announced that it was providing €2 million for manufacturing equipment to allow for expanded production of the Unidose device, which is used for delivery of Opvee intranasal nalmefene. Aptar’s efforts to expand capacity worldwide included the opening of a new facility in Mumbai, India at the end of 2023.
Aptar also said that it will add more capacity for manufacturing of child-resistant, senior-friendly closures for nasal decongestant sprays. In 2017, the company announced that it would move manufacturing of the child-resistant nasal pump to the Congers site.
Aptar Pharma President Gael Touya commented, “Our Aptar Pharma business in North America has shown robust growth in recent years, with increasing customer demand across all product lines. This expansion is a key step in the next phase of our global expansion program, designed to continue to meet the growing needs of our customers in the region, which will ultimately benefit patients.”
Aptar Pharma North America VP and General Manager Isabelle Menard added, “The expansion of our Congers facility provides a larger state-of-the-art manufacturing space, not only for the expansion of our well-established operations, but also to fuel further localization to support the needs of our US customers.”
Read the Aptar press release.
